BiotechTube

[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pancreatic Ductal Adenocarcinoma

Conditions

Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma

Trial Timeline

Apr 28, 2025 → May 28, 2032

NCT ID
NCT06710756

About [203Pb]Pb-PSV359 + [212Pb]Pb-PSV359

[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359 is a phase 1/2 stage product being developed by Perspective Therapeutics for Pancreatic Ductal Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06710756. Target conditions include Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer.

What happened to similar drugs?

9 of 20 similar drugs in Pancreatic Ductal Adenocarcinoma were approved

Approved (9) Terminated (4) Active (11)
✅DalteparinEisaiApproved
✅CREONAbbVieApproved
✅Pancrelipase + PlaceboAbbVieApproved
✅Pancrelipase CapsulesAbbVieApproved
✅Chromogranin ANovartisApproved
✅Pasireotide + DiazoxideNovartisApproved
✅everolimusNovartisApproved

Hype Score Breakdown

Clinical
9
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06710756Phase 1/2Recruiting

Competing Products

20 competing products in Pancreatic Ductal Adenocarcinoma

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
pemetrexedEli LillyPhase 2
35
mFOLFIRINOX + RamucirumabEli LillyPhase 2
35
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
enzastaurin + gemcitabineEli LillyPhase 2
35
Cyclophosphamide + GVAX Pancreas Vaccine (GVAX) + Pembrolizumab + IMC-CS4Eli LillyPhase 1
29
RamucirumabEli LillyPhase 1/2
32
GEMZAR + ALIMTAEli LillyPhase 3
40
CS-1008 (humanized anti-DR5 antibody) + gemcitabineDaiichi SankyoPhase 2
35
exatecan mesylateDaiichi SankyoPhase 2
35
exatecan mesylate + gemcitabine hydrochlorideDaiichi SankyoPhase 3
40
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
AGS-1C4D4 + gemcitabineAstellas PharmaPhase 2
35
erlotinib + gemcitabine + nab-paclitaxelAstellas PharmaPhase 1
29
erlotinib hydrochloride + gemcitabine hydrochlorideAstellas PharmaPhase 1
29
AGS-1C4D4 + GemcitabineAstellas PharmaPhase 2
35
Tarceva (erlotinib HCl, OSI-774)Astellas PharmaPhase 3
40
Enzalutamide + Gemcitabine + Nab-paclitaxelAstellas PharmaPhase 1
29